29 out of 100
Which of the following drug acts by inhibiting tyrosine kinase activated by EGF receptor as well as HER2
Ans. D Lapatinib
- Lapatinib is a new oral drug that acts as a dual HER-2 and EGF-receptor tyrosine kinase inhibitor.
- It is recently approved for trastuzumab-resistant HER-2/neu positive metastatic breast cancer in combination with capecitabine
- Imatinib: inhibits tyrosine kinase activated due to abl-bcr gene fusion and is the drug of choice for CML and GIST.